Canntab Therapeutics (CSE:PILL, OTC:CTABF, FSE:TBF1) CFO Richard Goldstein was featured in an interview on Midas Letter. In the interview, Goldstein talked about the second round of cannabis legalization by Health Canada and the company’s five-year hemp supply agreement with FSD Pharma Inc, (CSE:HUGE) and World Class Extractions (WCE).

Canntab is a Canadian oral dosage formulation company engaged in the research and development of advanced pharmaceutical-grade formulations of cannabinoids. Canntab has developed a line of immediate-release, modified-release and extended-release oral dose products to be sold in Canada. Currently, Health Canada has permitted the sale of cannabis-based softgel, capsules and flower. However, Health Canada has not approved the sale of cannabis-based pills and edibles, among others, but is expected to do so on or before October 17, 2019. Goldstein believes that Health Canada will legalize edibles and other cannabis products before that date.


Canntab is also looking at expanding into the US, but its focus is on the large cannabis market in Mexico. The company has already established a distribution network in Mexico and will be exporting all of its products internationally from Canada, pending approval from Health Canada.

“Mexico is a great marketplace … There’s a large medical-user base in Mexico. It’s our understanding that, upon Health Canada approval, we should be able to distribute in Mexico,” said Goldstein.

Goldstein also touched on Canntab’s recent supply agreement. Last week, Canntab entered into a three-way, five-year hemp agreement with FSD Pharma and WCE for 1,000 kilograms of organic hemp to extract CBD oil, which will then be processed into gel capsules and tablets at FSD Pharma’s facility in Cobourg, Ontario.

To view the full video, click here.

Click here to connect with Canntab Therapeutics (CSE:PILL, OTC:CTABF, FSE:TBF1) for an Investor Presentation. 

Both locations expand access to the state’s widest-ranging inventory of medical cannabis products for Central Florida patients

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of two brand-new Central Florida dispensaries. The new Clearwater and Tampa locations mark the Company’s 81 st and 82 nd nationwide, respectively, widening patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the appointment of Bart Oates Esq., President of the NFL Alumni Association, to its Advisory Board.

Philip Young, CEO and Director of Lobe, stated, “We are honored to welcome Bart to our Advisory Board. His first-hand experience on and off the field are tremendously valuable as we continue our research involving mild traumatic brain injuries and PTSD. These issues are prevalent in contact sports and we believe that athletes will play a prominent role in the continued acceptance of psychedelic medicines as legitimate treatment. We look forward to working with Bart as we seek to forge long-term strategic relationships.”

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that it has submitted its dossier to the United Kingdom’s Regulatory Food Safety Agency (the “FSA”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005322/en/

Keep reading... Show less